🇺🇸 RELVAR 100 ELLIPTA in United States

8 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 8

Most-reported reactions

1. Atelectasis — 1 report (12.5%)
2. Cholecystitis — 1 report (12.5%)
3. Cholelithiasis — 1 report (12.5%)
4. Chronic Obstructive Pulmonary Disease — 1 report (12.5%)
5. Constipation — 1 report (12.5%)
6. Contusion — 1 report (12.5%)
7. Fall — 1 report (12.5%)
8. Flatulence — 1 report (12.5%)

Source database →

Frequently asked questions

Is RELVAR 100 ELLIPTA approved in United States?

RELVAR 100 ELLIPTA does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for RELVAR 100 ELLIPTA in United States?

GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.